Insider Buying: BlossomHill Therapeutics (NASDAQ:BLSM) Director Acquires $5,000,000.00 in Stock

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Director Bihua Chen acquired 312,500 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average cost of $16.00 per share, with a total value of $5,000,000.00. Following the transaction, the director owned 3,614,034 shares in the company, valued at approximately $57,824,544. The trade was a 9.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.

BlossomHill Therapeutics Stock Performance

BLSM opened at $16.24 on Thursday. BlossomHill Therapeutics, Inc. has a fifty-two week low of $15.25 and a fifty-two week high of $17.25.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.